InxMed Raised $15M in Series B+ Financing

InxMed, Nanjing, ChinaCompany that develops clinical-stage biotechnology products, based in the United States, raised $15M in Series B+ funding.

Theround was led Hyfinity Investments.

TheThe company plans to use the funds to speed up ongoing clinical trials for IN10018 for multiple types of cancer. inBoth the US and Canada are represented. ChinaIncluding the initiation pivotal trials inThe second half of the year, and more stroma-targeting pipelines into clinics inBoth the US and Canada are represented. China this year, and strengthen the R&D capabilities in Nanjing.

Established inThe end of 2018 Dr. Zaiqi Wang, Chief Executive Officer, InxMed is a clinical-stage biotech company that develops therapies targeting stroma microenvironment and solid tumor resistance and metastasis, especially drug development on anti PD-1/PD-L1 treatment drug resistance.

IN10018 is an effective and highly selective FAK inhibitor against adenosine Triphosphate competitive FAK. InxMedIt holds the exclusive rights to global development and commercial operations. IN10018 was granted a fast track designation by the U.S. Food Drug Administration (FDA) in August2021 and a breakthrough designation China National Medical Products Administration (NMPA) for the treatment of patients with platinum-resistant ovarian cancer.

The company, which plans to disclose more data on IN10018 at the Annual MeetingYou can find the American SocietyThis is Clinical Oncology in June2022 has formed a partnership with several multinational pharmaceutical companies including Merck, Roche Boehringer Ingelheim.



Leave a Comment